共 50 条
- [3] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs [J]. Scientific Reports, 13
- [8] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations [J]. The European Journal of Health Economics, 2020, 21 : 153 - 164
- [9] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 153 - 164
- [10] miRNAs and resistance to EGFR-TKIs in EGFR-mutant non-small cell lung cancer: beyond 'traditional mechanisms' of resistance [J]. ECANCERMEDICALSCIENCE, 2015, 9